Calcium‐Based Antimicrobial Peptide Compounds as a Novel Treatment for Chronic Cheilitis: A Controlled Clinical Trial
Journal of Cosmetic Dermatology · 2026-11 · 25 (11)
DOI: 10.1111/jocd.71239 ↗Abstract
ABSTRACT Background Chronic cheilitis refers to recurrent inflammation of the lips lasting for 3 months or longer. Commonly managed with topical corticosteroids or tacrolimus; however, these medications carry a risk of side effects. Calcium‐based antimicrobial peptide compounds (CAPCS) contain natural calcium derivatives and antimicrobial peptides that provide anti‐inflammatory and barrier‐supporting effects. We explored whether CAPCS lip balm could serve as an alternative to tacrolimus 0.03% for treating chronic cheilitis. Methods A total of 52 patients with chronic cheilitis participated in this double‐blind, controlled trial and were allocated to use CAPCS lip balm ( n = 26) or 0.03% tacrolimus ointment ( n = 26) for a period of 4 weeks. Clinical assessments were performed at baseline, Week 2, and Week 4. A 3‐month follow‐up visit was conducted to evaluate recurrence or sustained improvement. Results Forty‐five patients completed the 4‐week treatment. Both groups showed marked improvement from baseline by Week 4 ( p < 0.001), although the tacrolimus group showed a faster reduction at Week 2 (4.4 ± 4.3 vs. 6.7 ± 4.0, p = 0.028). CAPCS showed good tolerability, with two cases of mild adverse events (7.7%), in contrast to six events (23.1%) observed in the tacrolimus group. At the 3‐month follow‐up, patients who continued CAPCS use showed sustained improvement, while recurrence was more common among those who stopped treatment. Conclusions CAPCS lip balm demonstrated comparable efficacy to tacrolimus 0.03% ointment, was better tolerated, and may serve as a safe alternative or a maintenance option for chronic cheilitis.
EUVIMED